Immunomedics raises $37.2 million

By AuntMinnie.com staff writers

February 18, 2000 --

Monoclonal antibody developer Immunomedics has completed a private placement of 2.3 million shares of common stock to a group of investors, generating gross revenue of $37.2 million. The Morris Plains, NJ-based firm plans to use the proceeds to accelerate clinical development of therapeutic agent CEA-Cide. Phase I and II trials are underway for evaluating the agent in colorectal, pancreatic, lung, breast, ovarian and medullary thyroid cancers.

By AuntMinnie.com staff writers
February 18, 2000

Copyright © 2000 AuntMinnie.com

 
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: